Flex Pharma (FLKS) Tops Q2 EPS by 7c

Flex Pharma (NASDAQ: FLKS) reported Q2 EPS of ($0.51), $0.07 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $331 thousand versus the consensus estimate of $520 thousand.

For earnings history and earnings-related data on Flex Pharma (FLKS) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
• Forum Markets, Incorporated (FRMM) Tops Q2 EPS by 29c ; Offers Guidance